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Abstract
Background: Most treatment failure of buccal mucosal cancer post surgery is locoregional recurrence. We tried to
figure out how close the surgical margin being unsafe and needed further adjuvant treatment.
Methods: Between August 2000 and June 2008, a total of 110 patients with buccal mucosa carcinoma (25 with
stage I, 31 with stage II, 11 with stage III, and 43 with Stage IV classified according to the American Joint
Committee on Cancer 6
th edition) were treated with surgery alone (n = 32), surgery plus postoperative
radiotherapy (n = 38) or surgery plus adjuvant concurrent chemoradiotherapy (n = 40).
Main outcome measures: The primary endpoint was locoregional disease control.
Results: The median follow-up time at analysis was 25 months (range, 4-104 months). The 3-year locoregional
control rates were significantly different when a 3-mm surgical margin (≤3 versus >3 mm, 71% versus 95%, p =
0.04) but not a 5-mm margin (75% versus 92%, p = 0.22) was used as the cut-off level. We also found a
quantitative correlation between surgical margin and locoregional failure (hazard ratio, 2.16; 95% confidence
interval, 1.14 - 4.11; p = 0.019). Multivariate analysis identified pN classification and surgical margin as independent
factors affecting disease-free survival and locoregional control.
Conclusions: Narrow surgical margin ≤3 mm, but not 5 mm, is associated with high risk for locoregional
recurrence of buccal mucosa carcinoma. More aggressive treatment after surgery is suggested.
Background
The incidence of buccal mucosa carcinoma has rapidly
increased in Taiwan in recent decades; major risk factors
for this disease are smoking, alcohol drinking, and betel
nut chewing[1-3]. In patients with buccal mucosa carci-
noma, locoregional recurrence (rate, 30-80%) is the main
cause of treatment failure[4,5]. Several predictive factors
for locoregional recurrence have been reported: bone
erosion or invasion, positive surgical margin, perineural
infiltration or invasion, vascular invasion, lymph node
involvement, and extracapsular extension of tumor from
the involved lymph node[6].
To reduce the risk of locoregional recurrence, radical
surgery plus postoperative radiotherapy (RT) has been
recommended for locoreginally advanced disease [7-9].
More recently, two large-scale randomized trials by the
Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research Treatment of Can-
cer (EORTC) have demonstrated definitive benefits of
post-operative concurrent chemoradiotherapy (CCRT)
after radical surgery in patients with high-risk head-and-
neck cancers [10,11]. National Comprehensive Cancer
Network treatment guidelines recommend post-opera-
tive CCRT for patients with positive surgical margin or
nodal extracapsular extension. However, in our limited
treatment experience, patients with close surgical mar-
gins still have a high risk of locoregional recurrence. In
the literature, close surgical margins less than 3 mm[12]
or 5 mm[13-15] have been reported to associate with a
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any medium, provided the original work is properly cited.high risk of cancer recurrence. However, there is still no
universally agreed on definition of close surgical margin
in buccal mucosa carcinoma.
Hence, we conducted this study to explore the effect
of close surgical margin on outcome in patients with
buccal mucosa carcinoma; and more importantly, to
define close surgical margins in these patients. The pri-
mary endpoint was locoregional disease control and the
secondary endpoints were disease-free survival, disease-
specific survival, distant-metastatic survival, and overall
survival. Other prognostic factors were also analyzed.
Methods
Ethical considerations
The procedures we followed were in accordance with
the ethical standards of the committee on human
experimentation of our institution and with the Helsinki
Declaration of 1975, as revised in 1983. This study was
approved by the Institutional Review Board at Buddhist
Dalin Tzu Chi General Hospital before this study was
performed.
Patients and stage classification
The records of 134 patients with buccal mucosa carci-
noma, treated from August 2000 to June 2008, were ret-
rospectively reviewed. All patients received definitive
treatments and had no distant metastasis. Twenty-four
patients treated with CCRT alone (n = 7), RT alone
(n = 5), neoadjuvant therapy plus surgery (n = 6), or
who had a synchronous second primary (n = 6) were
excluded. Thus, the remaining 110 patients who under-
went radical surgery with or without adjuvant treat-
ments were analyzed. Cancer staging was classified
according to the American Joint Committee on Cancer,
the 6
th edition[16].
Treatment modality
Radical surgery consisted of wide excision with or with-
out flap reconstruction for primary tumor and of unilat-
eral or bilateral radical neck dissection for neck disease
management. Pathology reports were reviewed for prog-
nostic factor analysis. Adjuvant treatments were started
4-6 weeks after surgery, if indicated. Adjuvant CCRT
was indicated for positive margin, extracapsular nodal
spread, or combined any other 2 risk factors, including
perineural invasion, vascular permeation, pT3, pT4 or N
(+) nodal disease. Adjuvant RT was indicated for single
risk factor except positive margin and extracapsular
nodal spread.
For 78 irradiated patients, post-operative Intensity
Modulated Radiotherapy (IMRT) was carried out using
an inverse planning system (PLATO, Nucleotron Inc.,
Veenendaal, The Netherlands). The radiation field
encompassed the surgical bed of the primary tumor and
neck. The critical normal structures used for optimiza-
tion included the brain stem, spinal cord, parotid glands,
optic nerves, optic chiasm, lenses, and eyeballs. During
RT, electronic portal imaging was performed weekly for
verification. The prescribed doses delivered by external
beam RT were as follows: 70-72 Gy to the gross tumor
volume; 60-66 Gy to the high risk nodal region; and,
50-60 Gy to the low risk nodal region. Conventional RT
fractionation was given, namely 1.8-2.0 Gy per day and
5 days per week for 6-7 weeks. The spinal cord dose
was limited to 45 Gy.
Chemotherapy was given concurrently with and after
RT, if indicated. The chemotherapy protocol consisted of
a concurrent two-month course of cisplatin and fluorour-
acil (5-FU) followed by another 2-month course after RT,
with regimens of cisplatin (60-100 mg/m
2/day) on day 1
and 5-FU (1000 mg/m
2/day) on days 1-5. We evaluated
treatment toxicities by using the common toxicity criteria
of the National Cancer Institute, V2.0[17].
Statistical methods and definitions
Survival and follow-up times were calculated from the
day of pathological diagnosis to the day of last follow-up
or death. We used commercial statistical software (SPSS
version 12.0; SPSS Inc., Chicago, IL, USA) to conduct sta-
tistical analyses, as follows: the Kaplan-Meier method to
cumulatively estimate survival and disease-control rates;
the log-rank test to assess curve difference between
groups; Pearson’s c
2 test to evaluate differences between
variables; and, Cox proportional hazard regression to per-
form multivariate analysis for hazard ratio (HR) assess-
ment. For estimating the effective size, HR was provided
with a 95% confidence interval (CI) in addition to a con-
ventional p value. All tests were two-tailed and consid-
ered to be statistically significant when p < 0.05.
Surgical margin was defined as the distance between
the outer edge of the tumor and the cut edge of the spe-
cimen under a microscope.
Results
Characteristics of patients
For all 110 patients, most patients were men (93.6%,
103/110), and 93 patients (84.5%) had a history of betel
nut chewing. The treatment modalities were as follows:
surgery alone (S), 29.1% (32/110); surgery plus post-
operative RT (S + RT), 34.5% (38/110); and, surgery
plus CCRT (S + CCRT), 36.4% (40/110). Table 1 shows
the characteristics of the study participants and their
tumors, and Table 2 shows the cancer stage distribution.
After surgery, 56 patients had pathological stage I-II
disease and 54 patients had stage III-IV disease. The
incidences of neck nodal involvement were: 24% in all
110 patients, 20.0% in 70 pT1-2 patients, and 30% in
40 pT3-4 patients.
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The median follow-up time was 25 months (range,
4-104 months). The mean age was 53.7 years (range,
26-82 years). Surgical margin affected locoregional con-
trol: the narrower the surgical margin, the greater the
difference in locoregional control after treatment
(Figures 1, 2, 3 and 4; Table 3). Patients with surgical
margin ≤3 mm had a statistically significantly higher
risk for locoregional failure than those with surgical
margin more than 3 mm; the 3-year locoregional control
rates were 71% and 95%, respectively (p = 0.04). In mul-
tivariate analysis, surgical margin had a quantitative
effect on locoregional control (hazard ratio [HR], 2.16;
95% confidence interval [CI], 1.14 - 4.11).
For all patients, the rates of 3-year locoregional con-
trol, disease-free survival, disease-specific survival, dis-
tant metastasis-free survival, and overall survival were
73%, 70%, 84%, 96%, and 82%, respectively.
Prognostic factors
For univariate analysis, pathology stage, pN classification,
surgical margin, and nodal extracapsular spreading (ECS)
were significantly associated with survival (Table 4). The
pN classification and surgical margin also significantly
affected locoregional control. The pN classification (pN0
versus pN1-3) and surgical margin (≤2 versus >2 mm)
were the two most significant factors affecting clinical
outcome. However, for surgical margin (cut off at 3 mm),
the statistical significance of its association with locore-
gional control was only found at the clinical end point of
3 years.
In multivariate analysis, both pN classification and
surgical margin independently affected disease-free sur-
vival and locoregional control. Furthermore pN classifi-
cation also affected overall and disease-specific survivals
(Table 5).
Discussion
Synopsis of key findings
In this study, two major findings indicated that surgical
margin ≤3 mm, not 5 mm, was a useful pathological
parameter for predicting locoregional recurrence in
patients with buccal mucosa carcinoma treated surgi-
cally. First, the 3-year locoregional control rates were
significantly different at the cut-off value of 3 mm
(≤3 versus >3 mm, 71% versus 95%, p = 0.04), but not at
5m m( 7 5 %versus 92%, p =0 . 2 2 ) .S e c o n d ,w ef o u n da
quantitative correlation between surgical margin and
locoregional failure (HR, 2.16; 95% C.I., 1.14 - 4.11;
p = 0.019), which suggested that every 1 mm decrease
in surgical margin significantly increased the rate of
locoregional failure by 116%.
Table 1 Characteristics of 110 patients with buccal
mucosa carcinoma
Variable Number of patients %
Age
≤50 44 40.0
>50 66 60.0
Gender
Male 103 93.6
Female 7 6.4
pT
pT1-2 70 63.6
pT3-4 40 36.4
pN
pN0 84 76.4
pN1-3 26 23.6
Pathology stage
I-II 56 50.9
III-IV 54 49.1
Histologic differentiation
Well 6 5.5
Moderately 90 81.8
Poorly 12 10.9
NOS 2 1.8
Surgical margin
Positive 6 5.5
Negative 104 94.5
Treatment
S 32 29.1
S+RT 38 34.5
S+CCRT 40 36.4
Smoking
No 16 14.5
Yes 93 84.5
Unknown 1 1.0
Betel nut chewing
No 15 13.6
Yes 93 84.5
Unknown 2 1.8
Abbreviations: S, surgery alone; S+RT, surgery+radiotherapy; S + CCRT, surgery
+ concurrent chemoradiotherapy; NOS, not otherwise specified.
Table 2 Stage distribution in 110 patients with buccal
mucosa carcinoma, n (%)
Pathology stage (n, %) pN0 pN1 pN2 pN3
I (25, 22.7%) pT1 25 (22.7) 1 (0.9) 1 (0.9) 0
II (31, 28.2%) pT2 31 (28.2) 0 12 (10.9) 0
III (11, 10.0%) pT3 9 (8.2) 1 (0.9) 4 (3.6) 0
IV (43, 39.1%) pT4 19 (17.3) 2 (1.8) 5 (4.5) 0
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Figure 2 Kaplan-Meier estimates of locoregional control over a 5-year period according to 3 mm cut-off surgical margins.
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Figure 4 Kaplan-Meier estimates of locoregional control over a 5-year period according to 5 mm cut-off surgical margins.
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For patients with buccal mucosa carcinoma and positive
surgical margins, postoperative clinical outcome is poor
[18,19]. For patients with close surgical margins, the risk
for cancer recurrence is high [12,13,15]. However, how
many millimeters between the tumor and edge of the
specimen define a close surgical margin? More impor-
tantly, can this definition be used to make a treatment
recommendation after surgery? The answers to these
questions are still controversial. A previous study sug-
gested 3 mm was adequate to reduce the risk of cancer
recurrence [12], but most studies recommended 5 mm
[13-15]. In our study, surgical margin ≤3 mm tightly
associated with high locoregional recurrence rate in
patients with buccal mucosa carcinoma. Considering
survival as the endpoint, overall survival was signifi-
cantly poorer in patients with surgical margin ≤2m m
than in those with margin >2 mm (Table 4). In our
study, we also adjusted treatment modality. The treat-
ment results did not have significant difference. For a
close margin of ≤3 mm, more effective and safe drugs,
re-surgery or higher doses of radiotherapy should be
considered into multi-modal treatment strategy.
Thus, we would suggest that for locoregional control,
surgical margin of 3 mm, not 5 mm, may be a suitable
cut-off point to use for post-operative adjuvant therapy
decision making; however, for survival, surgical margin
of 2 mm may be the cut-off point at which stronger
post-operative treatment is recommended.
Several other post-operative prognostic factors were eval-
uated in our study. In agreement with other studies
[9,19-21], our study found that pN classification was the
most important prognostic factor for both survival and
locoregional control. The 3-year overall survival and locor-
egional control rates in patients with pN0 and pN1-3 dis-
eases were 96%/33% and 81%/46%, respectively (both
p values < 0.001; Tables 4 and 5), suggesting that intense
post-operative adjuvant therapy should be given to patients
with pN1-3 disease, and CCRT with or without targeted
therapy in a clinical trial setting should be considered.
ECS of involved lymph nodes has been found to be a
poor prognostic factor. Patients with both ECS and a
positive surgical margin had significantly poorer overall
survival than those without these risk factors [10,11,15].
In our study, ECS significantly associated with poor sur-
vival only in univariate but not in multivariate analysis.
Table 3 The 3-year disease-free survival and locoregional control according to surgical margins
Surgical margin Disease-free survival (%) p Locoregional control (%) p
1m m
≤1 mm 56 0.02* 59 <0.01*
>1 mm 77 81
HR, univariate 0.4 (95% CI, 0.19-0.86) 0.02 0.4 (95% CI, 0.16-0.80) 0.01
HR, multivariate 0.2 (95% CI, 0.06-0.72) 0.02 0.2 (95% CI, 0.05-0.67) 0.01
2m m
≤2 mm 59 <0.01* 64 <0.01*
>2 mm 93 97
HR, univariate 0.1 (95% CI, 0.03-0.62) <0.01 0.1 (95% CI, 0.01-0.64) 0.02
HR, multivariate 0.1 (95% CI, 0.01-0.60) 0.01 0.1 (95% CI, 0.01-0.72) 0.02
3m m
≤3 mm 67 0.06* 71 0.04*
>3 mm 91 95
HR, univariate 0.3 (95% CI, 0.06-1.16) 0.08 0.2 (95% CI, 0.02-1.19) 0.07
HR, multivariate 0.2 (95% CI, 0.03-1.86) 0.17 0.3 (95% CI, 0.03-2.12) 0.21
4m m
≤4 mm 69 0.13* 73 0.09*
>4 mm 89 94
HR, univariate 0.3 (95% CI, 0.08-1.49) 0.15 0.2 (95% CI, 0.03-1.53) 0.12
HR, multivariate 0.3 (95% CI, 0.04-2.16) 0.22 0.3 (95% CI, 0.04-2.52) 0.28
5m m
≤5 mm 72 0.36* 75 0.22*
>5 mm 86 92
HR, univariate 0.5 (95% CI, 0.12-2.22) 0.37 0.3 (95% CI, 0.04-2.30) 0.25
HR, multivariate 0.5 (95% CI, 0.07-4.22) 0.56 0.6 (95% CI, 0.08-4.80) 0.63
Abbreviation: HR, hazard ratio; 95% CI, 95% confidence interval.
*, p values were calculated by using Kaplan-Meier method; other non-specified p values were calculated by using Cox proportional hazard regression.
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The main strength of this study is that the medical and
surgical records were complete and the pathologies were
well defined for all 110 patients included with buccal
mucosa carcinoma treated with radical surgery; the
homogeneity of this study population increases the clini-
cal applicability of our results to such patients.
Limitations of this study
This study had two main limitations: a retrospective
design and small number of cases. Thus, the conclusions
of this study should be confirmed by further investiga-
tions. Despite these limitations, our data showed that a
surgical margin of more than 3 mm may be relatively
Table 4 The 3-year clinical outcomes according to prognostic factors
Factor Overall
survival (%)
p Disease-specific
survival (%)
p Disease-free
survival (%)
p Locoregional
control (%)
p Distant metastasis-free
survival (%)
p
Age
≤50/
>50
78/85 0.61 78/89 0.24 66/72 0.59 72/74 0.97 93/98 0.18
Gender
Male/
Female
84/51 0.1 86/60 0.32 71/42 0.51 74/56 0.9 97/80 0.14
pT
pT1-2/
pT3-4
87/75 0.08 89/79 0.15 72/66 0.65 73/73 0.88 98/92 0.13
pN
pN0/
pN1-3
96/33* a 98/34* a 81/32* a 81/46* a 100/79* A
Pathology
stage
I-II/III-IV 98/66* a 100/69* a 81/58* 0.01 81/65 0.07 100/92* 0.04
Grade
1/2+3 83/81 0.99 100/83 0.35 100/67 0.17 100/71 0.2 100/96 0.63
Surgical
margin
(+)/(-) 63/83 0.26 63/86 0.16 44/71 0.21 44/75 0.12 100/96 0.63
≤2/>2
(mm)
64/94* 0.02 66/97* 0.01 59/93* b 64/97* b 91/97 0.37
≤3/>3
(mm)
70/91 0.18 71/95 0.09 67/91 0.06 71/95* 0.04 93/95 0.74
ECS
(+)/(-) 25/77* a 33/77* b 50/71* 0.01 75/73 0.62 75/76 0.02
PNI
(+)/(-) 72/85 0.23 72/80 0.15 64/71 0.32 73/73 0.64 91/96 0.41
Bone
invasion
(+)/(-) 85/91 0.2 85/91 0.2 55/70 0.46 55/74 0.3 100/98 0.63
Skin
invasion
(+)/(-) 76/94 0.19 82/94 0.48 56/64 0.78 67/64 0.27 84/100 0.05
*, Statistically significant difference; a, p < 0.001; b, p < 0.01; PNI, perineural invasion; ECS, extracapsular spread; (+), positive; (-), negative.
Table 5 Prognostic factors affecting clinical outcome in
multivariate analysis
Factor HR (95% CI) p
Overall survival
Nodal status (pN0 vs. pN1-3) 27.1 (3.19-229.32) <0.01
Disease-specific survival
Nodal status (pN0 vs. pN1-3) 28.3 (3.33-241.53) <0.01
Disease-free survival
Nodal status (pN0 vs. pN1-3) 7.3 (2.11-25.44) <0.01
Surgical margin (≤2m mvs. >2 mm) 0.1 (0.01-0.60) 0.02
Locoregional control
Nodal status (pN0 vs. pN1-3) 5.9 (1.59-21.92) <0.01
Surgical margin (≤2m mvs. >2 mm) 0.1 (0.01-0.72) 0.02
Abbreviations: HR, hazard ratio; 95% CI, 95% confidence interval.
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mucosa carcinoma.
Conclusion
More aggressive post-operative therapy is suggested for
patients with buccal mucosa carcinoma excised with a
close margin of ≤3 mm.
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